Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

著者: Lori Muffly, Marcelo C. Pasquini, Michael J. Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K. Ballen, Ashish Bajel, Frédéric Baron, Minoo Battiwalla, Amer Beitinjaneh, Jean‐Yves Cahn, Mathew Carabasi, Yi‐Bin Chen, Saurabh Chhabra, Stefan O. Ciurea, Edward A. Copelan, Anita D’Souza, John Edwards, James M. Foran, César O. Freytes, Henry C. Fung, Robert Peter Gale, Sergio Giralt, Shahrukh K. Hashmi, Gerhard Hildebrandt, Vincent T. Ho, Ann A. Jakubowski, Hillard M. Lazarus, Marlise R. Luskin, Rodrigo Martino, Richard T. Maziarz, Philip L. McCarthy, Taiga Nishihori, Rebecca L. Olin, Richard F. Olsson, Attaphol Pawarode, Edward Peres, Andrew R. Rezvani, David A. Rizzieri, Bipin N. Savani, Harry C. Schouten, Mitchell Sabloff, Matthew D. Seftel, Sachiko Seo, Mohamed L. Sorror, Jeff Szer, Baldeep Wirk, William A. Wood, Andrew Artz - Blood 2017 被引用: 296

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.